Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31

Vaccine

Volumn 24, Issue 26, 2006, Pages 5452-5460

  Agger, Else Marie ^a   Rosenkrands, Ida ^a   Olsen, Anja Weinreich ^a   Hatch, Graham ^b   Williams, Ann ^b   Kritsch, Constantia ^c   Lingnau, Karen ^c   von Gabain, Alexander ^c   Andersen, Claire Swetman ^a   Korsholm, Karen Smith ^a   Andersen, Peter ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c INTERCELL AG   (Austria)

Author keywords

Adjuvant; Tuberculosis; Vaccine

Indexed keywords

ANTIGEN 85B ESAT 6 PROTEIN; BCG VACCINE; GAMMA INTERFERON; IC 31; IMMUNOLOGICAL ADJUVANT; LYSYLLEUCYLLYSYLLEUCYL 5 LYSYLLEUCYLLYSINE; MYCOBACTERIUM VACCINE; OLIGODEOXYNUCLEOTIDE; PEPTIDE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GUINEA PIG; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SIGNAL TRANSDUCTION; TH1 CELL; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; FEMALE; GUINEA PIGS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT PROTEINS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 33744815623     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.072     Document Type: Article

References (33)

1. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 97 25 (2000) 13853-13858
2. Skeiky Y.A., Alderson M.R., Ovendale P.J., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172 12 (2004) 7618-7628
3. Olsen A.W., van Pinxteren L.A., Okkels L.M., Rasmussen P.B., and Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69 5 (2001) 2773-2778
4. McShane H., Pathan A.A., Sander C.R., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 11 (2004) 1240-1244
5. Brandt L., Skeiky Y.A., Alderson M.R., et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72 11 (2004) 6622-6632
6. Brandt L., Feino Cunha J., Weinreich Olsen A., et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 70 2 (2002) 672-678
7. Medzhitov R., Preston-Hurlburt P., and Janeway Jr. C.A. A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature 388 6640 (1997) 394-397
8. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 199 (2004) 227-250
9. Kritsch C.E., Berger A., Heinrich-Cseh C., Bugajska-Schretter A., and Zauner W. Separation and quantification of a novel two-component vaccine adjuvant. J Chromatogr B Anal Technol Biomed Life Sci 822 1-2 (2005) 263-270
10. Olsen A.W., Williams A., Okkels L.M., Hatch G., and Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72 10 (2004) 6148-6150
11. Langermans J.A., Doherty T.M., Vervenne R.A., et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23 21 (2005) 2740-2750
12. Schellack C., Prinz K., Egyed A., Fritz J., Wittmann B., Ginzler M., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24 26 (2006) 5461-5472
13. Weldingh K., Rosenkrands I., Jacobsen S., Rasmussen P.B., Elhay M.J., and Andersen P. Two-dimensional electrophoresis for analysis of Mycobacterium tuberculosis culture filtrate and purification and characterization of six novel proteins. Infect Immun 66 8 (1998) 3492-3500
14. Andersen P., Askgaard D., Ljungqvist L., Bentzon M.W., and Heron I. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun 59 (1991) 1558-1563
15. Harboe M., Malin A.S., Dockrell H.S., et al. B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis. Infect Immun 66 2 (1998) 717-723
16. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 62 6 (1994) 2536-2544
17. Rosenkrands I., Agger E.M., Olsen A.W., et al. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect Immun 73 9 (2005) 5817-5826
18. Martin R.M., and Lew A.M. Is IgG2a a good Th1 marker in mice?. Immunol Today 19 1 (1998) 49
19. James B.W., Williams A., and Marsh P.D. The physiology and pathogenicity of Mycobacterium tuberculosis grown under controlled conditions in a defined medium. J Appl Microbiol 88 4 (2000) 669-677
20. Lindblad E.B., Elhay M.J., Silva R., Appelberg R., and Andersen P. Adjuvant modulation of immune response to tuberculosis sub-unit vaccines. Infect Immun 65 2 (1997) 623-629
21. McShane H., Pathan A.A., Sander C.R., Goonetilleke N.P., Fletcher H.A., and Hill A.V. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 85 1-2 (2005) 47-52
22. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun 73 8 (2005) 4676-4683
23. Oliveira G.A., Wetzel K., Calvo-Calle J.M., et al. Safety and enhanced immunogenicity of a Hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 73 6 (2005) 3587-3597
24. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 72 11 (2004) 6519-6527
25. Claassen E., de Leeuw W., de Greeve P., Hendriksen C., and Boersma W. Freund's complete adjuvant: an effective but disagreeable formula. Res Immunol 143 5 (1992) 478-483
26. Schwarz K., Storni T., Manolova V., et al. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol 33 6 (2003) 1465-1470
27. Jarrossay D., Napolitani G., Colonna M., Sallusto F., and Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31 11 (2001) 3388-3393
28. Kadowaki N., Ho S., Antonenko S., et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med 194 6 (2001) 863-869
29. Maurer T., Heit A., Hochrein H., et al. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol 32 8 (2002) 2356-2364
30. Speiser D.E., Lienard D., Rufer N., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 3 (2005) 739-746
31. Cooper C.L., Davis H.L., Morris M.L., et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22 23-24 (2004) 3136-3143
32. Parra M., Pickett T., Delogu G., et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun 72 12 (2004) 6799-6805
33. Dass C.R. Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. J Mol Med 82 9 (2004) 579-591